NPA Statement on Treatment of Opioid Use Disorder

National Physicians Alliance Statement on Treatment of Opioid Use Disorder

The National Physicians Alliance supports access to evidence-based treatment for opioid use disorder, including medication-assisted therapies such as methadone, buprenorphine and naltrexone.  Only 1 in 10 people with substance use disorders currently receive treatment.  We hope that Health and Human Services Secretary Tom Price will continue to promote access to effective treatments including medication-assisted therapy, as a means of improving the lives of people with opioid use disorder.  No family should have to cope with the death of loved one from an opioid overdose because of a lack of available treatment.
According to NPA board member Anthony J. Accurso, MD, General Internist and Addictionologist from NYC, “Medication-Assisted Therapies (MAT) for opioid use disorder are evidence-based and proven to retain patients in treatment and reduce the risk of overdose. The increasing presence of fentanyl and carfentil in street-acquired heroin makes the current risk of overdose even greater.  People with opioid-use disorder who obtain buprenorphine or methadone are not subject to the uncertainty of the heroin composition, and are therefore safer.”


Becky Martin, Advocacy Director
National Physicians Alliance
c: 941/518-7051